#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Ureteric cancer Dementia Angiosarcoma Mantle cell lymphoma recurrent Raynaud's phenomenon Pleomorphic leiomyosarcoma Kearns-Sayre syndrome B-cell small lymphocytic lymphoma refractory Gaucher's disease type III Malignant glioma Epilepsy Transitional cell carcinoma Ventricular fibrillation Acute leukaemia Synovial sarcoma metastatic More trials…

    Learn about Rare Diseases

    Primary immunodeficiency syndrome Adrenocortical carcinoma – Basic Information Marginal zone lymphoma refractory – Diagnostics Mucopolysaccharidosis I Ornithine transcarbamoylase deficiency – Diagnostics Pituitary-dependent Cushing’s syndrome – Life with Disease Friedreich’s ataxia – Diagnostics Combined immunodeficiency Testicular leiomyosarcoma – Treatment Haemophilia B without inhibitors – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Quercus Robur Pollen Extract Acemetacin Tyrosine Odm-208 Prilocaine VGA039 Liraglutide Mexiletine Rbl012.2 Nefopam Amitriptyline ACARBOSE Cilazapril Iodine (123I) Iobenguane Nacystelyn Dexamethasone Acetate Ph. Eur. Clopidogrel Transpocart19 Sulfamethizole Brentuximab Vedotin More therapies…

    Learn about Your Condition

    Hypomagnesaemia Osteosarcoma recurrent Neurofibromatosis C3 glomerulopathy Undifferentiated sarcoma Ewing's sarcoma metastatic Bacteraemia Benign prostatic hyperplasia Mantle cell lymphoma Haemoptysis Aneurysm ruptured Urinary tract infection Breast cancer Cancer pain Breast cancer metastatic More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • Study of ONL1204 eye injections to slow vision loss in patients with age-related macular degeneration and geographic atrophy

    Recruiting

    2 1
    Investigated Drugs:
    • XELAFASLATIDE
    Austria Czechia Germany Greece Hungary Italy +3

  • Study of intrathecal S230815 to evaluate safety and effectiveness in children with KCNT1-related Developmental and Epileptic Encephalopathy

    Recruiting

    2 1 1
    Investigated Drugs:
    • S230815-2
    France Italy Spain

  • Study of etentamig and iberdomide treatment for patients with relapsed or refractory multiple myeloma

    Recruiting

    1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Iberdomide
    France The Netherlands Norway

  • Study of nadofaragene firadenovec alone or with gemcitabine, docetaxel or pembrolizumab in adults with non-muscle invasive bladder cancer who did not respond to BCG therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • NADOFARAGENE FIRADENOVEC
    • Docetaxel
    • Gemcitabine Hydrochloride
    Czechia Denmark France Poland Spain

  • Study comparing standard and reduced intensity treatment in patients with acute myeloid leukemia or chronic lymphocytic leukemia who have no detectable disease after initial therapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Mitoxantrone Hydrochloride
    • Vinblastine Sulfate
    • Cladribine
    France Germany Poland

  • Study of Glofitamab and Pirtobrutinib Treatment in Patients with Mantle Cell Lymphoma Who Have Failed Previous Therapy and in Previously Untreated Patients

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Mantle cell lymphoma
    Investigated Drugs:
    • Glofitamab
    • Obinutuzumab
    • Pirtobrutinib
    Denmark Germany Norway Spain Sweden
Previous Page
1 … 131 132 133 134 135 … 1,648
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!